CentoXome® Gold

Highest medical quality at the most attractive price, Whole Exome TRIO testing

Making genetic testing of the highest quality universally available is a top priority for us. We are proud to announce the new release of CentoXome® Gold, whole exome TRIO testing with in-depth medical report and validation of the sequencing results including an extended clinical report

CentoXome® Gold - Key Features

  • Turnaround time of 45-60 days at the most attractive price
  • TRIO sequencing (index patient plus parents) and validation of the sequencing results including an extended clinical report
  • 95% target bp covered > 10X at 70-100x average coverage
  • Reportable variants in > 60% of the cases
  • Medical reporting by using Centogene’s proprietary variant database, CentoMD®
  • CAP, CLIA and ISO certification and accreditation

CentoXome® Platinum

Satisfying the highest requirements

Some cases require urgent attention (e.g. prenatal testing) and a superior coverage depth.
The CentoXome® Platinum service has the following additional unique quality characteristics:

  • 95% target bp covered > 20X at 100-130x average coverage
  • Express turnaround time of less than 15 days

The several thousand whole exome cases diagnosed at Centogene have demonstrated the true and proven clinical utility of CentoXome®. Most importantly, we have accumulated a huge body of medical experience which we utilize in every new patient testing. In the medical diagnostic process, informed decision-making can have a critical impact on the patient´s life; therefore we want to share this accumulated knowledge with you.

When is whole exome sequencing required?

For several patients the combination of symptoms does not allow to suspect certain single genetic causes with a high certainty. Therefore medical answers are likely to be obtained only through the sequencing of complete coding region, i.e. the whole exome. We particularly recommend indicating whole exome sequencing for patients with:

  1. epilepsy;
  2. neurodevelopmental disorders;
  3. bone diseases;
  4. metabolic disorders;
  5. cardiomyopathy;
  6. short stature;
  7. complex dysmorphia;
  8. SCID;
  9. immunological disorders;
  10. dementia;
  11. autism;
  12. blindness.

Detailed insights can be found in our cases studies and scientific publications.

Why is whole exome sequencing better than single gene or panel sequencing?

For complex and unclear symptoms exploring several single genes or gene panels is costly and time consuming. Furthermore, delayed diagnosis has a dramatic impact on the patient’s quality of life. Whole exome sequencing provides information on all genes enabling a quicker and more cost-effective diagnostic solution.

Why Centogene?

Centogene is a world leader in the processing and clinical interpretation of genetic data for rare diseases and for oncology predisposition testing. We have more than 10 years of experience and have already processed several thousand whole exome cases. Clearly structured, in-depth medical reports and solid collaborations with our partners are also core components of our service. Centogene adheres to the highest medical quality standards as our processes and laboratory are CAP/CLIA accredited, and we promise to always walk the extra mile to provide truly clinically relevant test results.

If you are interested in obtaining further information, please visit our homepage or contact us at any time
(+49 381-203652-222; crd(at)centogene(dot)com).

If you have any questions or comments, please do not hesitate to contact us.

Best regards,

Doreen Niemann
Senior Director Strategic Communication
Centogene AG


Centogene AG
Schillingallee 68
18057 Rostock


Responsible: Doreen Niemann
USt-IdNr.: DE813228872